Skip to content
Screener

Arrowhead Research ARWR Business Segments — Research And Development Expense, Excluding Noncash Expense

Similar metrics at other companies

Capricor Therapeutics logo
CAPRSingle Reportable — Research And Development Expense Excluding Noncash Expense
$23.97M+50.2%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
UroGen Pharma logo
URGNNoncash Inprocess Research And Development Expense
$0
UroGen Pharma logo
URGNNoncash Inprocess Research And Development Expense
$0
Helios Technologies logo
HLIOUnallocated Expenses — Research And Development Expense
$0
Dianthus Therapeutics logo
DNTHDiscovery Expenses — Research And Development Expense
$1.36M+51.4%

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.28B+445%
Enterprise value$12.2B+446%
P/S19.7×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept arwr:ResearchAndDevelopmentExpenseExcludingNoncashExpense.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025Six Months Ended March 31, 2026Six Months Ended March 31, 2025
Candidate costs$99,449$71,191$204,439$148,087
Discovery costs18,49814,80640,32627,742
Salaries33,54626,90763,58554,052
Facilities related7,5956,73715,69714,487
Total research and development expense, excluding non-cash expense$159,088$119,641$324,047$244,368
Stock compensation8,2977,88814,65515,437
Depreciation and amortization5,8685,57311,75410,299
Total research and development expense$173,253$133,102$350,456$270,104

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's business segments — research and development expense, excluding noncash expense?
Arrowhead Research (ARWR) reported business segments — research and development expense, excluding noncash expense of $159.09M in Q1 2026.
How has Arrowhead Research's business segments — research and development expense, excluding noncash expense changed year-over-year?
Arrowhead Research's business segments — research and development expense, excluding noncash expense increased by 33.0% year-over-year, from $119.64M to $159.09M.
What does business segments — research and development expense, excluding noncash expense mean?
Measures the cash-based expenditures dedicated to research and development, excluding non-cash items such as stock-based compensation and depreciation. This provides a clearer view of the actual cash burn rate associated with the company's R&D efforts. It is a critical metric for assessing the sustainability of the company's innovation strategy.

Ask your AI about Arrowhead Research's business segments — research and development expense, excluding noncash expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude